BioPharmSignal logoBioPharmSignal

Biotech News

Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

Twist Bioscience Corporation (TWST)Twist Bioscience CorporationFinancing

Synthesis of structurally complex and highly-engineered protein sequences to enable acceptance of approximately 99.5% of clonal gene orders and 99.9% of all DNA products Complex synthesis capabilities to support further advancement of AI-enabled drug discovery and nucleic acid therapeutics SOUTH

Related news

TWSTTwist Bioscience Corporation2026-02-17 12:00 EST

Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

TWSTTwist Bioscience Corporation2026-08-05 03:45 EST

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

View all latest news

Twist Bioscience Corporation

Synthetic Biology Platform Twist Bioscience manufactures customizable synthetic DNA and related biological products at scale. Its platform is designed to improve the speed, throughput and precision of research and development workflows. Oligos and Genes Core products include oligonucleotides, genes and complex DNA constructs used by...

Recent company news

TWSTTwist Bioscience Corporation2026-08-05 03:45 EST

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

TWSTTwist Bioscience Corporation2026-08-04 20:01 EST

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

TWSTTwist Bioscience Corporation2026-08-04 12:00 EST

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

TWSTTwist Bioscience Corporation2026-08-03 11:15 EST

Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results

TWSTTwist Bioscience Corporation2026-07-15 12:00 EST

Twist Bioscience to Report Fiscal 2026 Third Quarter Financial Results on Monday, August 3, 2026

Stock data

Close
109.08 USD
Market cap
4.37B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States